The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia
Günalp Uzun, Karina Althaus, Anurag Singh, Peter Mӧller, Ulf Ziemann, Annerose Mengel, Peter Rosenberger, Martina Guthoff, Gabor C. Petzold, Jens Müller, Martin Büchsel, Katharina Feil, Hans Henkes, Nils Heyne, Matthias Maschke, Caroline Limpach, Simon Nagel, Ulrich J. Sachs, Falko Fend, Tamam Bakchoul
Abstract
SF3B1 MT patients compared with 40% among those with WT. reclassified our patients based on IWG SF3B1 new proposal criteria. 1 Notably, 175 patients were classified as MDS-SF3B1 by the new proposed criteria, 145 patients with SF3B1 MT not meeting the new proposed criteria, and 1412 SF3B1 WT MDS patients (Table The median OS was 120 months (95% CI, 77-164 months), 55 months (95% CI, 42-69 months), and 31.5 months (95% CI, 28-35 months), respectively (P , .005; Figure The median leukemia-free survival was not reached among all SF3B1 MT patients compared with 58 months among SF3B1 WT patients (P , .005) (Figure The rate of AML transformation was 4.7%, 22%, and 38%, respectively (P , .005). t-MDS was observed in 10%, 9%, and 17% of the 3 above-mentioned groups. Excluding t-MDS, the median OS was 142, 57, and 36 months, respectively (P , .005). There was no difference in response rates to erythroid stimulating agents, hypomethylating agents, and lenalidomide between patients classified as SF3B1 by IWG new criteria compared with other SF3B1 MT MDS.